 |
|  |
Oct-17-19 | Resumed |
BofA/Merrill |
Neutral |
$90 |
|
Aug-16-19 | Initiated |
SVB Leerink |
Outperform |
|
|
Jul-03-19 | Initiated |
Mizuho |
Buy |
$97 |
|
May-28-19 | Initiated |
Goldman |
Neutral |
|
|
May-13-19 | Upgrade |
Atlantic Equities |
Neutral → Overweight |
|
|
Oct-16-18 | Reiterated |
Citigroup |
Buy |
$70 → $79 |
|
Oct-09-18 | Resumed |
Guggenheim |
Buy |
|
|
Apr-23-18 | Upgrade |
Goldman |
Neutral → Buy |
|
|
Apr-17-18 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
Apr-05-18 | Upgrade |
Barclays |
Equal Weight → Overweight |
$62 → $64 |
|
Mar-12-18 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
Feb-14-18 | Reiterated |
Leerink Partners |
Mkt Perform |
$67 → $66 |
|
Feb-07-18 | Reiterated |
Morgan Stanley |
Equal-Weight |
$60 → $63 |
|
Jan-16-18 | Upgrade |
SunTrust |
Hold → Buy |
|
|
Nov-28-17 | Resumed |
BofA/Merrill |
Buy |
$64 |
|
Nov-24-17 | Reiterated |
Deutsche Bank |
Hold |
$62 → $59 |
|
Oct-31-17 | Upgrade |
Jefferies |
Underperform → Hold |
|
|
Oct-30-17 | Downgrade |
SunTrust |
Buy → Hold |
|
|
Oct-30-17 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
Oct-30-17 | Downgrade |
Barclays |
Overweight → Equal Weight |
$72 → $62 |
|
|
 |
Dec-05-19 09:58AM | Bristol-Myers' Orencia Gets Breakthrough Therapy Tag for GvHD Zacks |
09:07AM | J&J Stock Witnesses Volatility in '19: What to Expect in 2020 Zacks |
06:45AM | LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer Business Wire |
Dec-04-19 05:52PM | Bayer and Teva Double Down on Worst M&A Deals of Decade GuruFocus.com |
10:08AM | Bristol-Myers' Reblozyl to be Reviewed by FDA Committee Zacks |
10:02AM | Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks |
09:22AM | Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC Zacks |
03:55AM | Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer (Revised) Zacks |
Dec-03-19 05:03PM | Merck Cyberattacks $1.3 Billion Question: Was It an Act of War? Bloomberg |
02:41PM | Merck Cyberattack Raises $1.3 Billion Legal Question Bloomberg |
10:45AM | Seattle Genetics, Astellas Tie Up With Merck for Cancer Study Zacks |
09:24AM | Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer Zacks |
08:17AM | Large-Cap Pharmaceuticals Industry Prospects Bright for 2020 Zacks |
07:59AM | The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga |
Dec-02-19 08:57AM | Merck Stock Gains as FDA Accelerates Review of New Use for Blockbuster Cancer Drug Barrons.com |
08:30AM | AstraZeneca's (AZN) Imfinzi Gets FDA Priority Tag for SCLC Zacks |
06:55AM | Merck to Present at the Evercore ISI HealthCONx Conference 2019 Business Wire |
06:45AM | FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC) Business Wire |
Nov-30-19 12:03PM | Heres the real difference between women and men when it comes to stock-market investing MarketWatch |
Nov-29-19 11:21AM | The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab Zacks |
Nov-28-19 09:31AM | Why Is Merck (MRK) Up 1.6% Since Last Earnings Report? Zacks |
08:44AM | Here's Why Merck's (MRK) Shares Are Up This Year Zacks |
07:09AM | Esperion's Promising Drugs Under Review, Funds a Concern Zacks |
Nov-27-19 03:53PM | Top Research Reports for Merck, Eli Lilly & Charter Communications Zacks |
10:12AM | Merck's Keytruda Gets Nod in China for Difficult Lung Cancer Zacks |
07:59AM | [video]Merck Wins Drug Approval and Part of a Court Case; Here's How to Trade the Stock TheStreet.com |
07:26AM | The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen Benzinga |
07:10AM | Pfizer/Astellas Xtandi Gets Nod in China for Prostate Cancer Zacks |
Nov-26-19 05:05PM | US Indexes Close Higher Tuesday, Best Buy Rises 10% GuruFocus.com |
03:52PM | Merck, Walt Disney share gains lead Dow's nearly 75-point jump MarketWatch |
06:45AM | Mercks KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy Business Wire |
Nov-25-19 09:45AM | Intel, Merck share gains lead Dow's 100-point jump MarketWatch |
09:01AM | Hedge Funds Are Optimistic About Merck & Co., Inc. (MRK) Insider Monkey |
06:45AM | New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors PR Newswire |
Nov-23-19 03:41PM | Pfizer Is the Dows Worst Stock. A New Strategy Makes It Worth Another Look. Barrons.com |
Nov-22-19 04:31PM | Dow Jones Today: Trade Progress Pushes Stocks, Healthcare Helps Dow InvestorPlace |
11:31AM | Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes Zacks |
09:41AM | NewsBreak: Trump Looks to Let Florida, Others Import Prescription Drugs Investing.com |
08:45AM | Merck (MRK) is an Incredible Growth Stock: 3 Reasons Why Zacks |
Nov-21-19 05:58PM | Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal Zacks |
10:17AM | Dow drops 75 points on losses for shares of Travelers, Walgreens Boots MarketWatch |
10:00AM | Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer Zacks |
07:00AM | Market Morning: GM Sues Fiat, Pharma Fights for Pricing Privacy, More Opioid Lawsuits, Trade Deal Troubles Market Exclusive |
Nov-20-19 11:01AM | Your three-stock survival kit for 2020 packed by Nuveens top stock-market strategist MarketWatch |
08:41AM | Medicines Company Up on Rumors of Potential Buyout by Novartis Zacks |
06:45AM | European Commission Approves Two New Regimens of Mercks KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) Business Wire |
06:30AM | Keytruda researcher launches cancer-focused Werewolf Therapeutics with $56M American City Business Journals |
Nov-19-19 12:59PM | Merck raises quarterly dividend, to yield more than peers and the S&P 500 MarketWatch |
12:43PM | Merck Announces First-Quarter 2020 Dividend Business Wire |
10:33AM | Drug Legislation Likely to Dry Up Biotech Funding GuruFocus.com |
10:32AM | Merck's Heart Failure Candidate Meets Goal in Phase III Study Zacks |
09:23AM | Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies Zacks |
Nov-18-19 04:57PM | Gluware teams with Juniper to diagnose complex wireless networks American City Business Journals |
10:27AM | Medicines Company Posts Full Inclisiran Data From ASCVD Study Zacks |
10:24AM | Beyond Meat Is Shaking Up the Meat Industry. Animal-Health Stocks Could Take a Hit, Too. Barrons.com |
09:18AM | Bristol-Myers Gets FTC Clearance for Celgene Acquisition Zacks |
07:46AM | Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date Zacks |
07:19AM | How to Generate Retirement Income With a Total Return Strategy Barrons.com |
07:12AM | 5 Blue-Chip Stocks to Buy as Dow Breezes Past 28,000 Zacks |
06:30AM | Merck and Bayers Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure Business Wire |
12:18AM | Thiel Marks Palantirs Asia Push with $150 Million Japan Venture Bloomberg |
Nov-17-19 07:07AM | Hedge Funds Open Kimono: 5 Best Healthcare Stocks To Buy Insider Monkey |
Nov-15-19 09:23AM | AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status Zacks |
07:12AM | Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates Zacks |
06:45AM | BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration Business Wire |
06:41AM | 4 Big Drugmakers to Bet on After a Great Earnings Season Zacks |
05:33AM | Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings Bloomberg |
Nov-14-19 05:26PM | Livongo Bounces Back After Revenue Guidance Boost GuruFocus.com |
11:44AM | Cisco, Merck share losses lead Dow's nearly 75-point drop MarketWatch |
09:44AM | FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes Zacks |
09:44AM | Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss Zacks |
06:55AM | US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review Business Wire |
02:19AM | Merck posts higher profit and revenue as it lifts sales forecast MarketWatch |
02:10AM | UPDATE 2-Merck KGaA raises 2019 guidance after Versum takeover Reuters |
01:22AM | Merck KGaA raises 2019 sales, earnings guidance in wake of Versum takeover Reuters |
Nov-13-19 02:32PM | Ex-Novartis exec named as Flagship's matchmaker for Big Pharma partnerships American City Business Journals |
10:51AM | Dow flat despite gains in Procter & Gamble, Coca-Cola shares MarketWatch |
Nov-12-19 04:40PM | US Indexes End the Day Higher Tuesday GuruFocus.com |
02:47PM | Should You Worry About Merck & Co., Inc.'s (NYSE:MRK) CEO Salary Level? Simply Wall St. |
10:28AM | Dow's nearly 75-point climb highlighted by gains for shares of Merck, Walt Disney MarketWatch |
09:00AM | NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®) GlobeNewswire |
08:05AM | Merck's Ebola Vaccine Gets Conditional Approval in Europe Zacks |
07:59AM | Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review Zacks |
06:30AM | BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th GlobeNewswire |
Nov-11-19 04:23PM | Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study Zacks |
03:00PM | Mercks ERVEBO® Granted Conditional Approval in the European Union Business Wire |
10:28AM | The Zacks Analyst Blog Highlights: Mastercard, UnitedHealth, Merck, Qualcomm and CVS Health Zacks |
08:46AM | Novartis' Generics Unit to Buy Aspen's Japanese Operations Zacks |
Nov-09-19 11:50AM | Quit being fooled by fast-growing companies claiming to be tech firms when they just use technology MarketWatch |
Nov-08-19 03:06PM | Top Analyst Reports for Mastercard, UnitedHealth & Merck Zacks |
12:20PM | Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y Zacks |
10:04AM | The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co Zacks |
Nov-07-19 03:37PM | Kahn Brothers' 3rd-Quarter Update GuruFocus.com |
02:33PM | Teva climbs despite earnings miss Yahoo Finance Video |
01:06PM | P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook Moody's |
11:13AM | Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up Zacks |
11:04AM | Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks |
09:17AM | Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks Zacks |
06:44AM | UPDATE 1-Johnson & Johnson files for European approval of Ebola vaccine Reuters |
05:00AM | Merck- Value Expert Eyes Pharma Favorite MoneyShow |
|
|
|
 |
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fish. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; horse fertility management products; dog, cat, and horse vaccines; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Intec Pharma Ltd.; Nerviano Medical Sciences; Healthy Interactions, Inc.; Oncologie, Inc.; Themis Bioscience; I-MAB Biopharma Co., Ltd.; 4D pharma plc; and Promega Corporation. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. |
 |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Nally Michael | EVP, Chief Marketing Officer | Oct 30 | Option Exercise | 0.00 | 2,287 | 0 | 6,196 | Nov 01 05:07 PM | MIZELL STEVEN | EVP, Chief HR Officer | Oct 30 | Option Exercise | 0.00 | 4,574 | 0 | 4,574 | Nov 01 05:07 PM | Clyburn Frank | EVP, Chief Commercial Officer | Oct 30 | Option Exercise | 0.00 | 2,287 | 0 | 73,032 | Nov 01 05:06 PM | Scholefield James H | EVP,Chief Info&Digital Officer | Oct 30 | Option Exercise | 0.00 | 11,436 | 0 | 11,436 | Nov 01 05:04 PM | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 09 | Option Exercise | 0.00 | 6,427 | 0 | 77,951 | Aug 12 05:13 PM | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 09 | Sale | 85.09 | 6,427 | 546,850 | 71,524 | Aug 12 05:13 PM | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 08 | Option Exercise | 0.00 | 31,699 | 0 | 103,223 | Aug 12 05:13 PM | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Aug 08 | Sale | 85.01 | 31,699 | 2,694,789 | 71,524 | Aug 12 05:13 PM | Davis Robert M | EVP, Global Svcs & CFO | Jun 25 | Option Exercise | 0.00 | 216,718 | 0 | 354,378 | Jun 27 05:05 PM | Davis Robert M | EVP, Global Svcs & CFO | Jun 25 | Sale | 85.43 | 216,718 | 18,514,032 | 137,660 | Jun 27 05:05 PM | Karachun Rita A | Sr. VP Fince-Global Controller | May 10 | Option Exercise | 0.00 | 3,292 | 0 | 22,412 | May 13 05:06 PM | Clyburn Frank | EVP, Chief Commercial Officer | May 10 | Option Exercise | 0.00 | 4,389 | 0 | 71,993 | May 13 05:05 PM | Fleming Michael | SVP Chief Ethics & Com Officer | May 10 | Option Exercise | 0.00 | 1,509 | 0 | 3,317 | May 13 05:05 PM | Nally Michael | EVP, Chief Marketing Officer | May 10 | Option Exercise | 0.00 | 1,811 | 0 | 4,376 | May 13 05:06 PM | Clyburn Frank | EVP, Chief Commercial Officer | May 07 | Option Exercise | 39.29 | 25,000 | 982,250 | 92,604 | May 09 06:11 PM | Clyburn Frank | EVP, Chief Commercial Officer | May 07 | Sale | 77.73 | 25,000 | 1,943,183 | 67,604 | May 09 06:11 PM | Zachary Jennifer | EVP, General Counsel | May 04 | Option Exercise | 0.00 | 5,772 | 0 | 5,772 | May 07 07:42 PM | Nally Michael | EVP, Chief Marketing Officer | May 04 | Option Exercise | 0.00 | 1,298 | 0 | 2,935 | May 07 07:40 PM | Clyburn Frank | EVP, Chief Commercial Officer | May 04 | Option Exercise | 0.00 | 1,904 | 0 | 68,542 | May 07 07:37 PM | Karachun Rita A | Sr. VP Fince-Global Controller | May 04 | Option Exercise | 0.00 | 1,212 | 0 | 19,717 | May 07 08:32 PM | Fleming Michael | SVP Chief Ethics & Com Officer | May 04 | Option Exercise | 0.00 | 692 | 0 | 2,046 | May 07 08:32 PM | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | May 03 | Option Exercise | 39.29 | 35,000 | 1,375,150 | 106,064 | May 07 08:33 PM | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | May 03 | Sale | 80.00 | 35,000 | 2,800,000 | 71,064 | May 07 08:33 PM | Merck & Co., Inc. | 10% Owner | Apr 08 | Buy | 16.00 | 4,121,683 | 65,946,928 | 12,955,016 | Apr 09 06:27 PM | Davis Robert M | EVP, Global Svcs & CFO | Mar 25 | Option Exercise | 58.22 | 192,572 | 11,211,542 | 330,232 | Mar 27 05:45 PM | Davis Robert M | EVP, Global Svcs & CFO | Mar 25 | Sale | 82.38 | 192,572 | 15,863,119 | 137,660 | Mar 27 05:45 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 20 | Option Exercise | 39.29 | 192,736 | 7,572,597 | 990,451 | Mar 20 06:49 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 20 | Sale | 82.05 | 192,736 | 15,813,372 | 797,715 | Mar 20 06:49 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 13 | Option Exercise | 39.29 | 18,725 | 735,705 | 816,440 | Mar 14 06:38 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 13 | Sale | 82.00 | 18,725 | 1,535,454 | 797,715 | Mar 14 06:38 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 05 | Option Exercise | 39.29 | 6,961 | 273,498 | 804,676 | Mar 06 06:13 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 05 | Sale | 82.00 | 6,961 | 570,809 | 797,715 | Mar 06 06:13 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 04 | Option Exercise | 39.29 | 13,144 | 516,428 | 810,859 | Mar 06 06:13 PM | FRAZIER KENNETH C | Chairman, President & CEO | Mar 04 | Sale | 82.01 | 13,144 | 1,077,875 | 797,715 | Mar 06 06:13 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 22 | Option Exercise | 39.29 | 53,961 | 2,120,128 | 745,911 | Feb 22 05:16 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 22 | Sale | 80.02 | 53,961 | 4,318,089 | 691,950 | Feb 22 05:16 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 21 | Option Exercise | 39.29 | 41,992 | 1,649,866 | 733,942 | Feb 22 05:16 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 21 | Sale | 80.00 | 41,992 | 3,359,452 | 691,950 | Feb 22 05:16 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 19 | Option Exercise | 39.29 | 42,700 | 1,677,683 | 734,650 | Feb 19 05:35 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 19 | Sale | 80.02 | 42,700 | 3,416,944 | 691,950 | Feb 19 05:35 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 15 | Option Exercise | 39.29 | 92,913 | 3,650,552 | 784,863 | Feb 19 05:35 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 15 | Sale | 80.03 | 92,913 | 7,436,162 | 691,950 | Feb 19 05:35 PM | Karachun Rita A | Sr. VP Fince-Global Controller | Feb 14 | Option Exercise | 59.16 | 64,662 | 3,825,551 | 80,837 | Feb 14 06:02 PM | Karachun Rita A | Sr. VP Fince-Global Controller | Feb 14 | Sale | 78.96 | 64,662 | 5,105,951 | 16,175 | Feb 14 06:02 PM | WEEKS WENDELL P | Director | Feb 13 | Option Exercise | 24.30 | 5,000 | 121,500 | 5,100 | Feb 14 06:02 PM | WEEKS WENDELL P | Director | Feb 13 | Sale | 78.71 | 5,000 | 393,548 | 100 | Feb 14 06:02 PM | Chattopadhyay Sanat | Exe V-P & Pres. MMD | Feb 12 | Option Exercise | 38.18 | 73,727 | 2,815,241 | 125,194 | Feb 14 06:02 PM | Chattopadhyay Sanat | Exe V-P & Pres. MMD | Feb 12 | Sale | 78.62 | 73,727 | 5,796,306 | 51,467 | Feb 14 06:02 PM | BRUN LESLIE A | Director | Feb 08 | Option Exercise | 24.30 | 5,000 | 121,500 | 5,000 | Feb 11 05:33 PM | BRUN LESLIE A | Director | Feb 08 | Sale | 77.22 | 3,052 | 235,681 | 1,948 | Feb 11 05:33 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 05 | Option Exercise | 39.29 | 231,566 | 9,098,228 | 923,516 | Feb 06 05:30 PM | FRAZIER KENNETH C | Chairman, President & CEO | Feb 05 | Sale | 78.08 | 231,566 | 18,079,654 | 691,950 | Feb 06 05:30 PM |
|
 |
|
 |
|